Review

Farnesoid X receptor: a master regulator of hepatic triglyceride and glucose homeostasis

Yang JIAO 1, #, Yan LU 1, #, Xiao-ying LI 1, 2, *

1Shanghai Institute of Endocrinology and Metabolism, Department of Endocrine and Metabolic Diseases, Shanghai Clinical Center for Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China; 2The Key Laboratory of Endocrine Tumors and the Division of Endocrine and Metabolic Diseases, E-Institute of Shanghai Universities, Shanghai 200025, China

Non-alcoholic fatty liver disease (NAFLD) is characterized by the aberrant accumulation of triglycerides in hepatocytes in the absence of significant alcohol consumption, viral infection or other specific causes of liver disease. NAFLD has become a burgeoning health problem both worldwide and in China, but its pathogenesis remains poorly understood. Farnesoid X receptor (FXR), a member of the nuclear receptor (NR) superfamily, has been demonstrated to be the primary sensor for endogenous bile acids, and play a crucial role in hepatic triglyceride homeostasis. Deciphering the synergistic contributions of FXR to triglyceride metabolism is critical for discovering therapeutic agents in the treatment of NAFLD and hypertriglyceridemia.

Keywords: farnesoid X receptor; non-alcoholic fatty liver disease; liver; triglyceride metabolism; glucose metabolism; drug discovery

Acta Pharmacologica Sinica (2015) 36: 44–50; doi: 10.1038/aps.2014.116; published online 15 Dec 2014

Introduction

Non-alcoholic fatty liver disease (NAFLD) is characterized by the aberrant accumulation of triglycerides (TGs) in hepatocytes in the absence of significant alcohol consumption, viral infection, or other specific causes of liver disease. NAFLD currently affects 30% of Western individuals and 15% of the Chinese population[1, 2]. The disease comprises a spectrum of hepatic histological abnormalities, ranging from simple steatosis to steatohepatitis and cirrhosis, and may even progress to hepatocellular carcinoma. In addition, NAFLD is strongly associated with several cardiometabolic abnormalities, including type 2 diabetes mellitus (T2DM) and coronary heart disease[3, 4]. For instance, our previous study found that NAFLD was associated with atherosclerosis in middle-aged and elderly Chinese individuals, independent of conventional cardiovascular disease risk factors or metabolic syndrome[5].

The hallmark of NAFLD is intrahepatic TG accumulation, which results from an imbalance between the hepatic TG input and output. In the liver, TGs are primarily synthesized from two sources. (1) De novo lipogenesis (DNL), which is a complex process involving multiple metabolic reactions that begin with acetyl-coenzyme A (CoA). The rate of this process is tightly regulated by several nuclear transcription factors, such as sterol regulatory element binding protein 1c (SREBP-1c). SREBP-1c promotes DNL via binding to the promoter regions of lipogenic enzyme genes and enhancing their transcription. (2) Fatty acid (FA) uptake. FAs derived from the lipolysis of adipose tissues are released into the circulation and then transported to the liver by the hepatic artery and portal vein. Membrane proteins such as fatty acid transporter proteins (FATPs) direct the FA traffic from the circulation to the liver. Additionally, FAs in the liver have two main fates. (1) β-Oxidation, in which FAs can be oxidized in the mitochondria to produce ketone bodies, which are exported to provide fuel for other tissues. (2) Very low-density lipoprotein (VLDL) export, in which TGs can be assembled with a newly synthesized apolipoprotein B-100 (apoB-100) and secreted into the systemic circulation as a constituent of VLDLs[6]. Liver steatosis occurs when the TG homeostasis is disrupted due to an increase in DNL and FA uptake and a reduction in FA oxidation and VLDL export. However, the molecular mechanisms involved in the development of NAFLD remain poorly elucidated.

FXR gene and protein structure

Farnesoid X receptor (FXR, NR1H4), a member of the nuclear receptor superfamily, was originally cloned from a rat liver cDNA library in 1995[7, 8]. FXR was named on the basis of its
weak activation by supraphysiological levels of farnesoid, an intermediate of mevalonate metabolism\[7\]. Subsequent studies have demonstrated that specific bile acids (BAs), such as chenodeoxycholic acid (CDCA) and cholic acid (CA), are endogenous ligands for FXR\[8–11\]. There are two FXR genes: FXRα and FXRβ. FXRβ is a pseudogene in humans, although it serves as a lanosterol sensor and encodes a functional protein in rodents, rabbits and dogs\[12\]. Expressed from a single gene locus, FXRα encodes four isoforms (FXRa1, FXRa2, FXRa3, FXRa4) that result from two distinct promoters that initiate transcription from either exon 1 or exon 3 or the alternative RNA splicing of exon 5\[13,14\]. Although the four FXRa isoforms are expressed in a tissue-specific manner, the majority of the FXR target genes are regulated in an isoform-independent manner.

As a member of the NR superfamily, FXR shares a common architecture with other metabolic NRs: it is composed of an N-terminal ligand-independent activation function 1 (AF1) domain, a highly conserved DNA binding domain (DBD) that is connected by a flexible hinge region to a moderately conserved ligand binding domain (LBD), and a C-terminal ligand-dependent activation function 2 (AF2) domain\[15\]. FXR can form an obligate heterodimer with retinoid X receptor (RXR); therefore, it can be activated by both FXR and RXR ligands, such as BAs and 9-cis retinoic acid. In the absence of BAs, the FXR-RXR heterodimer binds to FXR response elements (FXREs) in the promoters of FXR target genes and in association with co-repressors, such as nuclear receptor co-repressor (NCoR), and silencing mediators for retinoic acid and thyroid hormone receptor (SMRT). Upon ligand binding, the co-repressors are released and co-activators are recruited, resulting in gene transcription. The FXREs contain inverted repeats of 2 AGGTCA half sites separated by one nucleotide (IRI)\[16,17\], although other variations have also been reported.

**FXR in hepatic triglyceride metabolism**

The relationship between BAs and TG metabolism was identified in the 1970s. The first evidence came from the observation that the administration of BAs, such as CDCA for the treatment of gallstones, resulted in decreased circulating TG levels\[17–19\], conversely, patients treated with BA-sequestering resins were found to have increased serum TG and VLDL levels\[17,20,21\]. Moreover, patients with monogenic familial hypertriglyceridemia displayed a defect in ileal BA absorption\[17\], whereas individuals with decreased BA synthesis due to a CYPT1A1 deficiency exhibited elevated serum TG concentrations\[22\]. These clinical observations suggest a direct relationship between BAs and TG metabolism. The importance of FXR in TG metabolism was further confirmed in FXR-deficient mice, which exhibited marked hepatosteatosis and hypertriglyceridemia\[23,24\]. In addition, FXR heterozygous mice demonstrated hepatosteatosis and hyperlipidemia following short-time high-fat diet (HFD) feeding\[25\]. The TG lowering effects of endogenous and synthetic FXR agonists have been evaluated in other rodent models as well. For instance, CA prevented hepatic TG accumulation and VLDL secretion in KK-A(\(y\)) mice, a mouse model of hypertriglyceridemia\[24\]. Moreover, the synthetic FXR agonist GW4066 was able to prevent liver steatosis in obese mice, such as the ob/ob and db/db models\[26\].

At the molecular level, FXR controls TG metabolism by regulating hepatic *de novo* lipogenesis. The activation of FXR suppresses the expression of SREBP-1c\[27\], a critical transcription factor that regulates hepatic TG synthesis by inducing key enzymes involved in lipogenesis, such as fatty acid synthase (FAS). The inhibition of SREBP-1c expression by FXR is mediated by a signaling cascade involving small heterodimer partner (SHP), which is able to blunt the action of liver X receptor (LXR) to induce SREBP-1c expression by interacting with liver receptor homologue 1 (LRH1)\[27\]. However, some studies have shown that transgenic mice with hepatic SHP overexpression developed liver steatosis due to the indirect activation of the peroxisome proliferator-activated receptor \(\gamma\) (PPAR\(\gamma\)) and SREBP-1c genes\[28\]. The deletion of SHP ameliorated the TG accumulation in ob/ob mice\[29,30\], suggesting that the roles of SHP in hepatic TG metabolism are diverse and complicated. Whether SHP is required for the inhibitory roles of FXR on DNL remains to be determined in future studies. A recent study indicated that the activation of FXR induces hepatic carboxylesterase 1, which is essential for FXR-controlled lipid homeostasis\[31\].

In addition to the suppression of *de novo* lipogenesis, FXR activation modulates FFA oxidation and TG clearance. In human hepatocytes, FXR agonists were shown to induce the expression of PPARα and its target genes to promote FFA oxidation\[32–34\]. FXR activation also inhibits the expression of microsomal triglyceride transfer protein (MTTP) via SHP, which in turn suppresses the hepatocyte nuclear factor 4a (HNF4a) transactivation of the MTTP promoter, thus decreasing hepatic VLDL production\[35,36\]. Moreover, FXR increases the activity of lipoprotein lipase (LPL) and promotes triglyceride hydrolysis by inducing APO CII expression\[37\]. Taken together, FXR activation reduces liver steatosis and hyperlipidemia by suppressing *de novo* lipogenesis and promoting TG oxidation and clearance (Figure 1A).

Given that obesity is closely associated with NAFLD, we speculate that FXR may be downregulated or dysfunctional in the livers of obese individuals. Indeed, we and others found that hepatic FXR expression is markedly reduced in obese animals and humans\[25\]. Mechanistic studies have further demonstrated that FXR is downregulated by the Yin Yang 1 (YY1) protein, which interrupts FXR gene transcription by binding to its first intron. In addition, we found that FXR was significantly downregulated in spontaneously aged mice\[38\] due to decreased HNF1α transcriptional activity by ER stress. Together, these studies suggest that FXR downregulation may play a causal role in obesity and aging-associated fatty liver (Figure 1B). Interestingly, FXR was also found to play an important role in the pathogenesis and progression of alcohol-induced hepatic TG retention. The FXR activity was functionally impaired by chronic ethanol ingestion in a murine model of alcoholic liver disease\[39\]. In addition, the activation of FXR by its specific agonists, WAY-362450 or INT747, rescued the...
FXR activity, thereby attenuating the ethanol-induced hepatic liver injury, steatosis and cholestasis. In addition, the activation of FXR was shown to protect against fructose-induced liver steatosis, suggesting several diverse roles for FXR in...
the prevention of hepatic TG accumulation.

**FXR in hepatic glucose metabolism**

A physiological role for FXR in hepatic carbohydrate metabolism has emerged in recent years as well. It has been demonstrated that the activation of FXR reduces hepatic gluconeogenesis, suppresses glycolysis and induces glycogen synthesis (Figure 1A). However, a group of in vitro studies focusing on the FXR regulation of gluconeogenic enzymes showed conflicting results. Some studies showed that BAs or the non-sterol FXR agonist GW4064 inhibit PEPCK and G6Pase mRNA expression in human hepatoma cells [42, 43], while other studies demonstrated that the activation of FXR increases PEPCK expression and glucose outflow in primary hepatocytes [44, 45]. Notably, a cholic acid-enriched diet markedly reduced the fasting blood glucose, as well as the hepatic PEPCK and G6Pase mRNA levels, in wild-type but not in FXR or SHP deficient mice, reinforcing the hypothesis that the FXR-SHP regulatory pathway represses gluconeogenesis [46]. In support of this concept, the overexpression of SHP also reduces gluconeogenic gene expression. Moreover, GW4064 treatment or the delivery of adenoviral constitutively activated FXR reduced hyperglycemia by inhibiting PEPCK and G6Pase expression in db/db and KK-A(y) diabetic mice [26, 46]. At the molecular level, PEPCK and G6Pase are positively regulated by hepatocyte nuclear factor 4a (HNF4a), glucocorticoid receptor α (GRα) and forkhead transcription factor 1 (FOXO1) in cooperation with peroxisome proliferator receptor γ coactivator-1α (PGC1α). FXR-induced SHP expression in turn disrupts the interactions of PGC1α with the abovementioned transcription factors and subsequently leads to a decrease in gluconeogenesis [48]. In addition, FXR was shown to repress the glucose-induced transcription of several glycolytic genes, such as the liver-type pyruvate kinase gene (L-PK), by inhibiting the transcriptional activity of carbohydrate response element binding protein (ChREBP) [47]. Moreover, glycogen synthesis can also be promoted via the FXR-mediated induction of GSK3β phosphorylation in db/db mice [26]. Consistent with this, the hepatic glycogen content is reduced in FXR-deficient mice [48].

FXR also modulates insulin signaling. The activation of FXR by natural and synthetic FXR agonists or the overexpression of FXR reduces plasma glucose levels and improves insulin sensitivity in diabetic mice [26, 46, 49]. Conversely, the inactivation of FXR disrupts glucose homeostasis, which was observed via impaired glucose tolerance and reduced insulin sensitivity [26, 46, 49]. FXR-deficient mice displayed a peripheral insulin resistance, which was reflected by a decrease in the glucose disposal rate [46]. The molecular mechanisms underlying the peripheral insulin resistance in FXR-deficient mice remain largely unknown. They may be associated with the elevated circulating FFA s and increased TG content in the peripheral tissues. Recently, several studies have suggested that the FXR-mediated insulin-sensitizing effect may partially involve the induction of fibroblast growth factor 19 (FGF19) and FGF21, two newly emerged metabolic cytokines [50, 51]. Given that adiponectin may mediate some of the metabolic effects of FGF21 on glucose homeostasis and insulin sensitivity [52], further studies are still needed to investigate the relationship between FXR and adipokines, including adiponectin. Notably, a recent study showed that the effect of vertical sleeve gastrectomy (VSG) on the reduction of body weight and the improvement of glucose tolerance was significantly abolished in FXR-deficient mice, suggesting that FXR plays a crucial role in the beneficial effects of VSG [53].

In addition, emerging studies have revealed that FXR may also regulate glucose homeostasis in other metabolic tissues. For instance, the ablation of FXR in pancreatic β cells resulted in impaired insulin secretion. FXR-deficient mice also displayed a reduction in adipose tissue mass, lower serum leptin concentrations, and elevated plasma free fatty acid levels. Mouse embryonic fibroblasts derived from FXR-deficient mice exhibited impaired adipocyte differentiation, suggesting a direct role for FXR in adipogenesis. Consistent with this, GW4064 enhanced the insulin-stimulated glucose uptake in differentiated 3T3-L1 adipocytes [53]. In addition, FXR agonists also improved insulin resistance in the visceral preadipocytes of obese mice and rats [49, 54]. FXR promotes adipocyte differentiation via the upregulation of PPARγ and interrupts the Wnt/beta-catenin pathways [55, 56]. In other words, FXR also plays an important role in the regulation of adipogenesis and insulin signaling.

**FXR agonist development**

BAs are capable of activating FXR to different extents due to their different structural modifications. Semi-synthetic and synthetic molecules with more affinity and specificity to FXR have also been developed. GW4064 was one of the first synthetic non-steroidal FXR agonists to be developed. It has been well-established that GW4064 markedly reduces hepatic lipid accumulation and improves dyslipidemia in genetically obese mouse models, such as ob/ob, db/db and KK-Ay mice, via SHP and SREBP-1c [57, 58]. GW4064 also attenuates hepatosteatosis in high-fat-diet-induced mice by repressing the lipid transporter gene CD36 [59]. GW4064 potently improves both hyperglycemia and hyperinsulinemia, as well as increasing hepatic glycogen storage in diabetic mice [30]. GW4064 is also considered to be a modulator of multiple G protein-coupled receptors.

Unlike the FXR agonist GW4064, WAY-362450 offers improved oral bioavailability for mice and rats [60]. The oral administration of WAY-362450 significantly lowered the serum TG and cholesterol levels and resulted in a significant reduction in aortic arch lesions in low-density lipoprotein receptor (LDLR)-deficient mice. Additionally, the serum TG and cholesterol levels were reduced by WAY-362450 in a dose dependent manner in diabetic mice (KK-Ay and db/db mice) and in fructose/cholesterol-fed rats [61]. WAY-362450 also significantly reduces the serum liver enzyme levels and decreases hepatic inflammation and fibrosis, as evidenced by the reduction of inflammatory cell infiltration and the hepatic gene expression of fibrosis markers [62]. However, WAY-362450 has not shown a positive impact on hepatic TG accumulation, which may limit its roles in the control of NAFLD.
INT747 (obeticholic acid, OCA), a 6α-ethyl derivative of CDCA, is a well-known clinically developed semi-synthetic FXR agonist that has entered clinical studies for NAFLD and NASH. Recent studies have shown that INT747 is capable of modulating lipid metabolism and protects obese rodents from insulin resistance via the inhibition of hepatic lipogenesis and peripheral fatty acid synthesis\cite{63-65}. INT747 can improve hepatic triglyceride and glucose tolerance by enhancing insulin signaling and suppressing hepatic gluconeogenesis\cite{64, 66}. INT747 also exerts anti-inflammatory and anti-fibrotic effects in the liver by suppressing nuclear factor (NF)-κB and subsequent hepatic satellite cell activation\cite{66, 67}.

In addition, INT747 has exhibited promising results in a phase IIa clinical trial in T2DM patients with NAFLD. The administration of 25 or 50 mg of INT747 for 6 weeks not only improved liver enzyme and lipid accumulation but also reduced markers of liver inflammation and fibrosis. Additionally, an increase in hepatic and peripheral glucose uptake was observed during hyperinsulinenic euglycemic clamp tests.

**Conclusion**

FXR plays a crucial beneficial role in hepatic triglyceride homeostasis, as well as in glucose metabolism and the regulation of bile acid homeostasis. FXR can lower hepatic TG content and serum TG levels and improve insulin resistance and hyperglycemia. Therefore, FXR agonists are promising for the treatment of NAFLD, dyslipidemia and type 2 diabetes.

**Acknowledgements**

This study is supported by grants from the National Key Basic Research Program of China (973 Program) (No 2012CB524902) and the National Natural Science Foundation of China (No 81200636, 81361128009, and 81370959).

**Abbreviations**

NAFLD, non-alcoholic fatty liver disease; FXR, farnesoid X receptor; NR, nuclear receptor; TG, triglyceride; T2DM, type 2 diabetes mellitus; DNL, de novo lipogenesis; CoA, coenzyme A; SREBP-1c, sterol regulatory element binding protein 1c; FA, fatty acid; FATPs, fatty acid transporter proteins; VLDL, very low-density lipoprotein; apoB-100, apolipoprotein B-100; CDCA, chenodeoxycholic acid; CA, cholic acid; AF1, activation function1; DBD, DNA binding domain; LBDB, ligand binding domain; AF2, activation function2; RXR, retinoid X receptor; FXREs, FXR response elements; NCoR, nuclear receptor co-repressor; SMRT, silencing mediators for retinoic acid receptor co-repressor; OCA, obeticholic acid.

**References**

1. Szczepaniak LS, Nurenberg P, Leonard D, Browning JD, Reingold JS, Grundy S, et al. Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. *Am J Physiol Endocrinol Metab* 2005; 288: E462–8.

2. Fan JG, Farrell GC. Epidemiology of non-alcoholic fatty liver disease in China. *J Hepatol* 2009; 50: 204–10.

3. Targher G, Marra F, Marchesini G. Increased risk of cardiovascular disease in non-alcoholic fatty liver disease: causal effect or epiphenomenon? *Diabetologia* 2008; 51: 1947–53.

4. Speliotes EK, Massaro JM, Hoffmann U, Vasan RS, Meigs JB, Sahani DV, et al. Fatty liver is associated with dyslipidemia and dysglycemia independent of visceral fat: the Framingham Heart Study. *Hepatology* 2010; 51: 1979–87.

5. Huang Y, Bi Y, Xu M, Ma Z, Xu Y, Wang T, et al. Nonalcoholic fatty liver disease is associated with atherosclerosis in middle-aged and elderly Chinese. *Arterioscler Thromb Vasc Biol* 2012; 32: 2321–6.

6. Cohen JC, Horton JD, Hobbs HH. Human fatty liver disease: old questions and new insights. *Science* 2011; 332: 1519–23.

7. Forman BM, Goode E, Chen J, Oro AE, Bradley DJ, Perlmann T, et al. Identification of a nuclear receptor that is activated by farnesol metabolites. *Cell* 1995; 81: 687–93.

8. Seol W, Choi HS, Moore DD. Isolation of proteins that interact specifically with the retinoid X receptor: two novel orphan receptors. *Mol Endocrinol* 1995; 9: 72–85.

9. Makishima M, Okamoto AY, Repa JJ, Tu H, Learned RM, Luk A, et al. Identification of a nuclear receptor for bile acids. *Science* 1999; 284: 1362–5.

10. Parks DJ, Blanchard SG, Bledsoe RK, Chandra G, Consler TG, Kliewer SA, et al. Bile acids: natural ligands for an orphan nuclear receptor. *Science* 1999; 284: 1365–8.

11. Wang H, Chen J, Hollister K, Sowers LC, Forman BM. Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. *Mol Cell* 1999; 3: 543–53.

12. Otte K, Kranz H, Kober I, Thompson P, Hoefer M, Haubold B, et al. Identification of farnesoid X receptor β as a novel mammalian nuclear receptor sensing lanosterol. *Mol Cell Biol* 2003; 23: 864–72.

13. Huber RM, Murphy K, Miao B, Link JS, Cunningham MR, Rupar MJ, et al. Generation of multiple farnesoid-X-receptor isoforms through the use of alternative promoters. *Gene* 2002; 290: 35–43.

14. Zhang Y, Kast-Woelbern HR, Edwards PA. Natural structural variants of the nuclear receptor farnesoid X receptor affect transcriptional activation. *J Biol Chem* 2003; 278: 104–10.

15. Pelllicciari R, Costamino G, Fiorucci S. Farnesoid X Receptor: from structure to potential clinical applications. *J Med Chem* 2005; 48: 5383–403.

16. Laffitte BA, Kast HR, Nguyen CM, Zavacki AM, Moore DD, Edwards PA. Identification of the DNA binding specificity and potential target genes for the farnesoid X-activated receptor. *J Biol Chem* 2000; 275: 10638–47.

17. Angelin B, Hershon KS, Brunzell JD. Bile acid metabolism in hereditary forms of hypertriglyceridermia: evidence for an increased synthesis rate in monogenic familial hypertriglyceridermia. *Proc Natl Acad Sci USA*.
Acad Sci U S A 1987; 84: 5434–8.
18 Bateson MC, Maclean D, Evans JR, Bouchier IA. Chenodeoxycholic acid therapy for hypertriglyceridaemia in men. Br J Clin Pharmacol 1987; 5: 249–54.
19 Bell GD, Lewis B, Petrie A, Dowling RH. Serum lipids in cholelithiasis: effect of chenodeoxycholic acid therapy. Br Med J 1973; 3: 520–3.
20 Beil U, Crouse JR, Einarsson K, Grundy SM. Effects of interruption of the enterohepatic circulation of bile acids on the transport of very low density-lipoprotein triglycerides. Metabolism 1982; 31: 438–44.
21 Crouse JR 3rd. Hypertriglyceridemia: a contraindication to the use of bile acid binding resins. Am J Med 1987; 83: 243–8.
22 Pullinger CR, Eng C, Salen G, Shefer S, Batta AK, Erickson SK, et al. Human cholesterol 7alpha-hydroxylase (CYP7A1) deficiency has a hypercholesterolemic phenotype. J Clin Invest 2002; 110: 109–17.
23 Sinal CJ, Tohkin M, Miyata M, Ward JM, Lambert G, Gonzalez FJ, et al. Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell 2000; 102: 731–44.
24 Bell GD, Lewis B, Petrie A, Dowling RH. Serum lipids in cholelithiasis: effect of chenodeoxycholic acid therapy. Br Med J 1973; 3: 520–3.
25 Coughlin SR, et al. The FXR agonist 6ECDCA reduces hepatic steatosis and oxidative stress induced by ethanol and low-protein diet in mice. Chem Biol Interact 2014; 217: 19–27.
26 Zhang Y, Lee FY, Barrera G, Lee H, Vales C, Gonzalez FJ, et al. Transcriptional integration of metabolism by the farnesoid X receptor attenuates hepatic injury in a murine model of alcoholic liver disease. Biochem Biophys Res Commun 2014; 443: 68–73.
27 Gonzalez FJ, Calkin AC, Tontonoz P. Farnesoid X-activated receptor induces apolipoprotein C-II transcription: a molecular mechanism linking plasma triglyceride levels to bile acids. Mol Endocrinol 2001; 15: 1720–8.
28 Xiong X, Wang X, Lu Y, Wang E, Zhang Z, Yang J, et al. Hepatic steatosis exacerbated by endoplasmic reticulum stress-mediated downregulation of FXR in aging mice. J Hepatology 2014; 60: 847–54.
29 Wu W, Zhu B, Peng X, Zhou M, Jia D, Gu J. Activation of farnesoid X receptor attenuates hepatic injury in a murine model of alcoholic liver disease. Biochem Biophys Res Commun 2014; 443: 68–73.
30 Parks DJ, Blanchard SG, Bledsoe RK, Chandra G, Consler TG, Kliewer SA, et al. The farnesoid X receptor: a new target for the effects of cholesterol catabolism to bile acids and of gluconeogenesis via a novel mechanism of transcription regulation linked to the fasted-to-fed cycle. J Biol Chem 2003; 278: 39124–32.
31 Liu X, Xue R, Ji L, Zhang X, Wu J, Gu J, et al. Activation of farnesoid X receptor (FXR) protects against fructose-induced liver steatosis via inflammatory inhibition and ADRP reduction. Biochem Biophys Res Commun 2014; 450: 117–23.
32 Beil U, Crouse JR, Einarsson K, Grundy SM. Effects of interruption of the enterohepatic circulation of bile acids on the transport of very low density-lipoprotein triglycerides. Metabolism 1982; 31: 438–44.
33 Xu J, Li Y, Chen WD, Xu Y, Yin L, Ge X, et al. Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proc Natl Acad Sci U S A 2006; 103: 1006–11.
34 Yang W, Zhu B, Peng X, Liu Y, et al. FXR regulates hepatic triglyceride metabolism by the farnesoid X receptor. Endocrinology 2005; 146: 984–91.
35 Cariou B, Duran-Sandoval D, Kuipers F, Staels B. Farnesoid X receptor: a new player in glucose metabolism? Endocrinology 2005; 146: 981–3.
36 Xu J, Li Y, Chen WD, Xu Y, Yin L, Ge X, et al. Hepatic carboxylesterase 1 is essential for both normal and farnesoid X receptor-controlled lipid homeostasis. Hepatology 2014; 59: 1761–71.
37 Pineda TI, Claudel T, Duval C, Kosyk V, Fruchtch J, Staels B. Bile acids induce the expression of the human perproliferator-activated receptor alpha gene via activation farnesoid X receptor. Mol Endocrinol 2003; 17: 259–72.
38 Savkur RS, Bramlett KS, Lívero FA, Stolf AM, Dreifuss AA, Bastos-Pereira AL, Chicosci R, de Oliveira LG, et al. The FXR agonist 6ECDCA reduces hepatic steatosis and oxidative stress induced by ethanol and low-protein diet in mice. Chem Biol 2014; 217: 19–27.
39 Cariou B, Duran-Sandoval D, Kuipers F, Staels B. Farnesoid X receptor: a new player in glucose metabolism? Endocrinology 2005; 146: 981–3.
40 Lívero FA, Stolf AM, Dreifuss AA, Bastos-Pereira AL, Chicosci R, de Oliveira LG, et al. The FXR agonist 6ECDCA reduces hepatic steatosis and oxidative stress induced by ethanol and low-protein diet in mice. Chem Biol 2014; 217: 19–27.
41 Liu X, Xue R, Ji L, Zhang X, Wu J, Gu J, et al. Activation of farnesoid X receptor (FXR) protects against fructose-induced liver steatosis via inflammatory inhibition and ADRP reduction. Biochem Biophys Res Commun 2014; 450: 117–23.
42 Beil U, Crouse JR, Einarsson K, Grundy SM. Effects of interruption of the enterohepatic circulation of bile acids on the transport of very low density-lipoprotein triglycerides. Metabolism 1982; 31: 438–44.
43 Savkur RS, Bramlett KS, Lívero FA, Stolf AM, Dreifuss AA, Bastos-Pereira AL, Chicosci R, de Oliveira LG, et al. The FXR agonist 6ECDCA reduces hepatic steatosis and oxidative stress induced by ethanol and low-protein diet in mice. Chem Biol 2014; 217: 19–27.
44 Cariou B, Duran-Sandoval D, Kuipers F, Staels B. Farnesoid X receptor: a new player in glucose metabolism? Endocrinology 2005; 146: 981–3.
45 Ma K, Saha PK, Chan L, Moore DD. Farnesoid X receptor is essential for normal glucose homeostasis. J Clin Invest 2006; 116: 1102–9.
46 Caron S, Huaman Samanez C, Dehondt H, Ploton M, Briand O, Lien F, et al. Farnesoid X receptor inhibits the transcriptional activity of carbohydrate response element binding protein in human hepatocytes. Mol Cell Biol 2013; 33: 2202–11.
47 Cariou B, van Harmelen K, Duran-Sandoval D, van Dijk T, Greffhorst A, Bouchaert E, et al. Transient impairment of the adaptive response to fasting in FXR-deficient mice. FEBS Lett 2005; 579: 4076–80.
48 Cariou B, van Harmelen K, Duran-Sandoval D, van Dijk T, Greffhorst A, Abdelkarim M, et al. The farnesoid X receptor modulates adiposity and peripheral insulin sensitivity in mice. J Clin Chem 2006; 281: 11039–49.
49 Kurosu H, Choi M, Ogawa Y, Dickson AS, Goetz R, Eliseenkova AV, et al. Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor isomers determines metabolic activity of FGF19 and FGF21. J Biol Chem 2007; 282: 26687–95.
50 Cyphert HA, Ge X, Kohan AB, Salati LM, Zhang Y, Hillgartner FB. Activation of the farnesoid X receptor induces hepatic expression and secretion of fibroblast growth factor 21. J Biol Chem 2012; 287: 25123–38.
51 Lin Z, Tian H, Lam KS, Lin S, Hoo RC, Konishi M, et al. Adiponectin mediates the metabolic effects of FGF21 on glucose homeostasis and insulin sensitivity in mice. Cell Metab 2013; 17: 779–89.
52 Ryan KK, Tremaroli V, Ciemmensen C, Kovatcheva-Datchary P, Myronovych A, Karrns R, et al. FXR is a multifunctional target for the effects of vertical sleeve gastrectomy. Nature 2014; 509: 183–8.
rabbit model of MetS. J Endocrinol 2013; 218: 215–31.
55 Rizzo G, Disante M, Mencarelli A, Renga B, Gioiello A, Pellicciari R, et al. The farnesoid X receptor promotes adipocyte differentiation and regulates adipose cell function in vivo. Mol Pharmacol 2006; 70: 1164–73.
56 Abdelkarim M, Caron S, Duhem C, Prawitt J, Dumont J, Lucas A, et al. The farnesoid X receptor regulates adipocyte differentiation and function by promoting peroxisome proliferator-activated receptor-gamma and interfering with the Wnt/beta-catenin pathways. J Biol Chem 2010; 285: 36759–67.
57 Fuchs M. Non-alcoholic Fatty liver disease: the bile acid-activated farnesoid X receptor as an emerging treatment target. J Lipids 2012; 2012: 934396.
58 Fiorucci S, Rizzo G, Donini A, Distrutti E, Santucci L. Targeting farnesoid X receptor for liver and metabolic disorders. Trends Mol Med 2007; 13: 298–309.
59 Ma Y, Huang Y, Yan L, Gao M, Liu D. Synthetic FXR agonist GW4064 prevents diet-induced hepatic steatosis and insulin resistance. Pharm Res 2013; 30: 1447–57.
60 Flatt B, Martin R, Wang TL, Mahaney P, Murphy B, Gu XH, et al. Discovery of XL335 (WAY-362450), a highly potent, selective, and orally active agonist of the farnesoid X receptor (FXR). J Med Chem 2009; 52: 904–7.
61 Evans MJ, Mahaney PE, Borges-Marcucci L, Lai K, Wang S, Krueger JA, et al. A synthetic farnesoid X receptor (FXR) agonist promotes cholesterol lowering in models of dyslipidemia. Am J Physiol Gastrointest Liver Physiol 2009; 296: G543–52.
62 Zhang S, Wang J, Liu Q, Harnish DC. Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-alcoholic steatohepatitis. J Hepatol 2009; 51: 380–8.
63 Vignozzi L, Morelli A, Filippi S, Comeglio P, Chavalmane AK, Marchetta M, et al. Farnesoid X receptor activation improves erectile function in animal models of metabolic syndrome and diabetes. J Sex Med 2011; 8: 57–77.
64 Mencarelli A, Renga B, Distrutti E, Fiorucci S. Antiatherosclerotic effect of farnesoid X receptor. Am J Physio Heart Circ Physiol 2009; 296: H272–81.
65 Cipriani S, Mencarelli A, Palladino G, Fiorucci S. FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats. J Lipid Res 2010; 51: 771–84.
66 Wang YD, Chen WD, Wang M, Yu D, Forman BM, Huang W. Farnesoid X receptor antagonizes nuclear factor kappaB in hepatic inflammatory response. Hepatology 2008; 48: 1632–43.
67 Fiorucci S, Antonelli E, Rizzo G, Renga B, Mencarelli A, Riccardi L, et al. The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis. Gastroenterology 2004; 127: 1497–512.